Healthequity, Inc.: Form 10-Q for the period ended Jul 31, 2024
Filed with the SEC on Sep 3, 2024 and accepted by EDGAR at Sep 3, 2024, 20:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-05-01 to 2024-07-31 | $299.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-02-01 to 2024-07-31 | $587.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-05-01 to 2024-07-31 | $95.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2024-02-01 to 2024-07-31 | $196.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-05-01 to 2024-07-31 | $204.1m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-02-01 to 2024-07-31 | $391.2m | us-gaap:GrossProfit |
| Research and development | 3 months2024-05-01 to 2024-07-31 | $58.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-02-01 to 2024-07-31 | $114.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-05-01 to 2024-07-31 | $58.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-02-01 to 2024-07-31 | $100.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-05-01 to 2024-07-31 | $15.4m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-02-01 to 2024-07-31 | $27.2m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-05-01 to 2024-07-31 | $10.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-02-01 to 2024-07-31 | $15.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-05-01 to 2024-07-31 | $35.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-02-01 to 2024-07-31 | $64.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-05-01 to 2024-07-31 | $0.40 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-02-01 to 2024-07-31 | $0.73 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-05-01 to 2024-07-31 | $0.41 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-02-01 to 2024-07-31 | $0.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-05-01 to 2024-07-31 | 88,646,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-02-01 to 2024-07-31 | 88,606,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-02-01 to 2024-07-31 | $173.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-02-01 to 2024-07-31 | $1.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-07-31 | $326.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-07-31 | $495.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-07-31 | $3.51bn | us-gaap:Assets |
| Current liabilities | At period end2024-07-31 | $120.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-07-31 | $1.36bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-07-31 | $1.10bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-07-31 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-07-31 | $2.16bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001428336-24-000102. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.